Faster time to market, less funds: How to survive as a BioTech Startup?

The climate of overall uncertainty in markets is leading to a lower tolerance of uncertainty by investors: this translates into higher pressure on invested companies, especially Biotech start-ups, to deliver

Healthcare Shapers Perspectives Guest: Craig A. DeLarge, MBA, MPHDigital Health Strategist, The Digital Mental Health Project A tipping point is approaching where the majority of humanity will use digital devices

Healthcare Shapers Perspectives Guest: Kathy LetendrePresident, Letendre & Associates LLC Now, more than ever, organizations need clarity. For some healthcare organizations, the crisis of the past year became a strategic

Healthcare Shapers Perspectives Guest: Erkan Hassan, PharmD, FCCMChief Clinical Officer, Sepsis Program Optimization Innovative technology alone does not ensure success.  Clinicians and technology groups are accustomed to working in divergent

Personalisierte Medizin: Fortschritt – nur für wenige, oder doch für alle?

Personalised medicine is the topic at medical congresses and attracts the crowds. The hottest topics are cell & gene therapies and RNA therapies.  The two approved cell therapies, Kymriah (Novartis)